Clinical Trial Update: Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety of adding sargramostim (GM-CSF) to chemotherapy in patients with refractory myeloid cancers; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Anemia
• Anemia with Ringed Sideroblasts
• Blastic-phase Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Status: COMPLETED